In this podcast we’ll hear life science and biotech CEOs tell their stories about their experiences launching and growing a biotech firm. We publish a quarterly...
Shooting for the Stars with Astrocyte Pharmaceuticals
With over 1.5 million people suffering traumatic brain
injuries a year, 80,000 stroke victims, and millions of concussions, the impact that brain impairment has on society is not to be ignored. We spoke with William Korinek of Astrocyte Pharmaceuticals, who is developing neuroprotein therapies for these conditions.
Disclaimer
The information contained in this website and podcast are
purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be
construed as a recommendation or endorsement of any of the companies discussed.
Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to
update this information as changes occur.
--------
48:23
Knee-deep in meniscus redesign: the story of Atlanta’s OrthoPreserve
There are 1.4 million meniscus procedures performed in the US and Europe every single year. Most of those are meniscetomy which is when the meniscus is removed. The problem is that once it is gone, so is the cushioning that protects the knee joint and cartilage, accelerating arthritis. A quarter of people continue to have pain after a few years. Millions of people have this procedure and it’s not the best answer.
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
--------
35:02
Confronting the task of delivering scalable amounts of protein to a billion cows
Our guest today is Dr. Ivan Liachko, the CEO of Seattle-based Phase Genomics, a company whose core technology is ultra-long range genome sequencing. He’s also the founder of Genome Startup Day, dedicated to helping new biotech entrepreneurs transition from academic settings into industry and entrepreneurship.
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
--------
47:05
What Pharma really thinks about Startups
Tune in for this insightful podcast with David Weinstock,
the Vice President of Discovery Oncology at Merck, to find out what pharma investors really think when they are interviewing startups looking for funding.
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
--------
12:08
Meet the Reluctant Founder who is waging war on Antibiotic Resistant Infections!
Our guest today is another Atlanta luminary, Dr. Marvin
Whiteley, the founder and CSO of SynthBiome, Inc. Deaths are expected to increase over the next 20-30 years due to antibiotic resistant infections.
It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics.
How can this trend be stopped?
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an
investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim
Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information
conveyed in this material is accurate and is under no obligation to update this information as changes occur.
In this podcast we’ll hear life science and biotech CEOs tell their stories about their experiences launching and growing a biotech firm. We publish a quarterly newsletter on our biotech podcasts as well as other entrepreneurial insights. Please subscribe here: http://eepurl.com/h6Gwa5
Be ready for motivating stories of grit and determination, along with practical tips, strategies, and guidance from some of the leading minds in the field. Hosted by portfolio manager Tim Dougherty, episodes will be available on the third Wednesday of the month over Spotify.
UK